Maze Therapeutics to Participate in the 3rd Annual H.C. Wainwright BioConnect Investor Conference
Rhea-AI Summary
Maze Therapeutics (MAZE), a clinical-stage biopharmaceutical company focused on developing small molecule precision medicines for renal, metabolic and cardiovascular diseases, has announced its participation in the upcoming 3rd Annual H.C. Wainwright BioConnect Investor Conference. CEO Jason Coloma, Ph.D., will deliver a company overview presentation on Tuesday, May 20, 2025, at 11 a.m. ET.
The presentation will be accessible through the Investors section of Maze's website at mazetx.com, with a replay available for 60 days. One-on-one meetings with management can be arranged through H.C. Wainwright representatives.
Positive
- None.
Negative
- None.
News Market Reaction – MAZE
In the trading session that priced this news, MAZE declined 2.67%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SOUTH SAN FRANCISCO, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with renal, metabolic and cardiovascular diseases, today announced that Jason Coloma, Ph.D., chief executive officer of Maze Therapeutics, will present a company overview and participate in one-on-one meetings at the 3rd Annual H.C. Wainwright BioConnect Investor Conference on Tuesday, May 20, 2025.
The presentation will be held at 11 a.m. ET and will be available in the Investors section of the company's website at mazetx.com. A replay of the presentation will be archived for 60 days.
If you would like to request a one-on-one meeting with company management during the conference, please reach out to your H.C. Wainwright representative.
About Maze Therapeutics
Maze Therapeutics is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. The company is advancing a pipeline using its Compass platform, which provides insights into the genetic variants in disease and links them with the biological pathways that drive disease in specific patient groups. The company’s pipeline is led by two wholly owned lead programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for patients. For more information, please visit mazetx.com, or follow us on LinkedIn and X.
IR/Corporate Contact:
Amy Bachrodt, Maze Therapeutics
abachrodt@mazetx.com
Media Contact:
Dan Budwick, 1AB
dan@1abmedia.com
